132 related articles for article (PubMed ID: 20124939)
1. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.
O'Dorisio TM; Krutzik SR; Woltering EA; Lindholm E; Joseph S; Gandolfi AE; Wang YZ; Boudreaux JP; Vinik AI; Go VL; Howe JR; Halfdanarson T; O'Dorisio MS; Mamikunian G
Pancreas; 2010 Jul; 39(5):611-6. PubMed ID: 20124939
[TBL] [Abstract][Full Text] [Related]
2. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
3. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
[TBL] [Abstract][Full Text] [Related]
4. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
6. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
[TBL] [Abstract][Full Text] [Related]
7. The occurrence of pancreastatin in tumours of the diffuse neuroendocrine system.
Bishop AE; Bretherton-Watt D; Hamid QA; Fahey M; Shepherd N; Valentino K; Tatemoto K; Ghatei MA; Bloom SR; Polak JM
Mol Cell Probes; 1988 Sep; 2(3):225-35. PubMed ID: 2851738
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.
Syversen U; Mignon M; Bonfils S; Kristensen A; Waldum HL
Acta Oncol; 1993; 32(2):161-5. PubMed ID: 8323758
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
Strosberg D; Schneider EB; Onesti J; Saunders N; Konda B; Shah M; Dillhoff M; Schmidt CR; Shirley LA
Ann Surg Oncol; 2018 Nov; 25(12):3613-3620. PubMed ID: 30182331
[TBL] [Abstract][Full Text] [Related]
10. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
Stridsberg M; Oberg K; Li Q; Engström U; Lundqvist G
J Endocrinol; 1995 Jan; 144(1):49-59. PubMed ID: 7891024
[TBL] [Abstract][Full Text] [Related]
11. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.
Syversen U; Jacobsen MB; O'Connor DT; Rønning K; Waldum HL
Neuropeptides; 1994 Mar; 26(3):201-6. PubMed ID: 8208366
[TBL] [Abstract][Full Text] [Related]
12. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?
Ito T; Igarashi H; Jensen RT
Pancreas; 2012 May; 41(4):505-7. PubMed ID: 22504376
[No Abstract] [Full Text] [Related]
13. Isolation and characterization of a tumor-derived human protein related to chromogranin A and its in vitro conversion to human pancreastatin-48.
Tamamura H; Ohta M; Yoshizawa K; Ono Y; Funakoshi A; Miyasaka K; Tateishi K; Jimi A; Yajima H; Fujii N
Eur J Biochem; 1990 Jul; 191(1):33-9. PubMed ID: 2165909
[TBL] [Abstract][Full Text] [Related]
14. Pancreastatin, a chromogranin A-derived peptide, inhibits transcription of the parathyroid hormone and chromogranin A genes and decreases the stability of the respective messenger ribonucleic acids in parathyroid cells in culture.
Zhang JX; Fasciotto BH; Darling DS; Cohn DV
Endocrinology; 1994 Mar; 134(3):1310-6. PubMed ID: 8119171
[TBL] [Abstract][Full Text] [Related]
15. Pancreastatin-like immunoreactivity in human carcinoid disease.
McGrath-Linden SJ; Johnston CF; O'Connor DT; Shaw C; Buchanan KD
Regul Pept; 1991 Mar; 33(1):55-70. PubMed ID: 2047545
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries.
Lloyd RV; Jin L; Qian X; Scheithauer BW; Young WF; Davis DH
Am J Pathol; 1995 May; 146(5):1188-98. PubMed ID: 7747813
[TBL] [Abstract][Full Text] [Related]
17. Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor.
Tateishi K; Kitayama N; Matsuoka Y; Funakoshi A
Life Sci; 1995; 57(9):889-95. PubMed ID: 7630318
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical localisation of pancreastatin and chromogranin A in porcine neuroendocrine tissues.
Jensen TB; Fahrenkrug J; Sundler F
Regul Pept; 1991 Oct; 36(2):283-97. PubMed ID: 1725220
[TBL] [Abstract][Full Text] [Related]
19. Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues.
Schmidt WE; Siegel EG; Lamberts R; Gallwitz B; Creutzfeldt W
Endocrinology; 1988 Sep; 123(3):1395-404. PubMed ID: 3042370
[TBL] [Abstract][Full Text] [Related]
20. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
